WACKER BIOSOLUTIONS

In 2020, WACKER BIOSOLUTIONS lifted its sales 1.3 percent to €246.1 million (2019: €243.0 million), chiefly due to volume growth in biologics and . Reduced volumes for a number of products had a dampening effect on sales growth. In regional terms, sales were very positive in Europe, but declined in the Americas and Asia.

At €38.1 million, was significantly higher year over year (2019: €31.1 million). The increase was due to volume growth and an improved cost structure. The EBITDA margin was 15.5 percent (2019: 12.8 percent).

Capital expenditures climbed year over year to €19.9 million (2019: €13.2 million). That was a rise of 50.8 percent. One investment focus was the new biologics production plant in Amsterdam.

As of December 31, 2020, the division had 764 employees (Dec. 31, 2019: 754).

 (XLSX:) Download XLS
Key Data: WACKER BIOSOLUTIONS

 

 

 

 

 

€ million

 

2020

 

2019

 

2018

 

2017

 

2016

 

 

 

 

 

 

 

 

 

 

 

Total sales

 

246.1

 

243.0

 

227.0

 

205.9

 

206.4

EBITDA

 

38.1

 

31.1

 

23.5

 

37.5

 

37.0

EBITDA margin (%)

 

15.5

 

12.8

 

10.4

 

18.2

 

17.9

EBIT

 

21.6

 

14.0

 

9.8

 

26.1

 

25.7

Capital expenditures

 

19.9

 

13.2

 

17.9

 

15.7

 

9.1

R&D expenses

 

5.7

 

6.4

 

6.3

 

6.0

 

6.2

Employees (December 31, number)

 

764

 

754

 

709

 

533

 

510

Cyclodextrins
Cyclodextrins belong to the family of cyclic oligosaccharides (i.e. ring-shaped sugar molecules). They are able to encapsulate foreign substances such as fragrances and to release active ingredients at a controlled rate. WACKER BIOSOLUTIONS produces and markets cyclodextrins.
EBITDA
Earnings before interest, taxes, depreciation and amortization.

todo Vorjahresvergleich